Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency Published, JLR Papers in Press, December 1, 2003. DOI 10.1194/jlr.M300198-JLR200

Our purpose was to compare HDL subpopulations, as determined by nondenaturing two-dimensional gel electrophoresis followed by immunoblotting for apolipoprotein A-I (apoA-I), apoA-II, apoA-IV, apoCs, and apoE in heterozygous, compound heterozygous, and homozygous subjects for cholesteryl ester transfer protein (CETP) deficiency and controls. Heterozygotes, compound heterozygotes, and homozygotes had CETP masses that were 30, 63, and more than 90% lower and HDL-cholesterol values that were 64, 168, and 203% higher than those in controls, respectively. Heterozygotes had ∼50% lower preβ-1 and more than 2-fold higher levels of α-1 and preα-1 particles than controls. Three of the five heterozygotes' α-1 particles also contained apoA-II, which was not seen in controls. Compound heterozygotes and homozygotes had very large particles not observed in controls and heterozygotes. These particles contained apoA-I, apoA-II, apoCs, and apoE. However, these subjects did not have decreased preβ-1 levels. Our data indicate that CETP deficiency results in the formation of very large HDL particles containing all of the major HDL apolipoproteins except for apoA-IV. We hypothesize that the HDL subpopulation profile of heterozygous CETP-deficient patients, especially those with high levels of α-1 containing apoA-I but no apoA-II, represent an improved anti-atherogenic state, although this might not be the case for compound heterozygotes and homozygotes with very large, undifferentiated HDL particles.

[1]  E. Schaefer,et al.  Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients DOI 10.1194/jlr.M200037-JLR200 , 2002, Journal of Lipid Research.

[2]  S. Yamashita,et al.  Polydisperse low-density lipoproteins in hyperalphalipoproteinemic chronic alcohol drinkers in association with marked reduction of cholesteryl ester transfer protein activity. , 1992, Metabolism: clinical and experimental.

[3]  M. Farnier,et al.  Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[4]  B F Asztalos,et al.  Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. , 2001, Atherosclerosis.

[5]  A. Tall,et al.  Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. , 1991, Journal of lipid research.

[6]  H. Mabuchi,et al.  Rapid detection and prevalence of cholesteryl ester transfer protein deficiency caused by an intron 14 splicing defect in hyperalphalipoproteinemia , 1993, Human Genetics.

[7]  S. Yamashita,et al.  Frequency of intron 14 splicing defect of cholesteryl ester transfer protein gene in the Japanese general population--relation between the mutation and hyperalphalipoproteinemia. , 1993, Atherosclerosis.

[8]  S. Yamashita,et al.  Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. , 1995, Atherosclerosis.

[9]  M. Lefevre,et al.  Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Jauhiainen,et al.  The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein* , 2001, The Journal of Biological Chemistry.

[11]  H. Suzuki,et al.  Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. , 1997, Journal of lipid research.

[12]  D. Rader,et al.  Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. , 1995, European journal of biochemistry.

[13]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[14]  H. Brewer,et al.  In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II. , 2002, Atherosclerosis.

[15]  N. Fidge High density lipoprotein receptors, binding proteins, and ligands. , 1999, Journal of lipid research.

[16]  S. Yamashita,et al.  Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. , 1990, The Journal of clinical investigation.

[17]  Gerard E. Dallal,et al.  Change in &agr;1 HDL Concentration Predicts Progression in Coronary Artery Stenosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[18]  L. Lagrost Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. , 1994, Biochimica et biophysica acta.

[19]  S. Yamashita,et al.  Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. , 1994, Journal of biochemistry.

[20]  H. Mabuchi,et al.  Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. , 1985, Atherosclerosis.

[21]  E. Schaefer,et al.  Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. , 2002, Atherosclerosis.

[22]  A. Reunanen,et al.  Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men , 2000, European journal of clinical investigation.

[23]  C. Sloop,et al.  Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. , 1993, Biochimica et biophysica acta.

[24]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[25]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[26]  E. Schaefer,et al.  Distribution of ApoA-I–Containing HDL Subpopulations in Patients With Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  S. Horiuchi,et al.  Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. , 1995, Journal of lipid research.

[28]  A. Jonas,et al.  Apolipoprotein A-II Modulates the Binding and Selective Lipid Uptake of Reconstituted High Density Lipoprotein by Scavenger Receptor BI* , 2001, The Journal of Biological Chemistry.

[29]  S. Yamashita,et al.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[30]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[31]  A. Tall,et al.  Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. , 1991, The Journal of clinical investigation.

[32]  Ken-ichiHirano,et al.  Genetic Cholesteryl Ester Transfer Protein Deficiency Is Extremely Frequent in the Omagari Area of Japan , 1997 .

[33]  S. Yokoyama,et al.  Rate of cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia. , 1985, Journal of biochemistry.

[34]  R. F. Johnston,et al.  Autoradiography using storage phosphor technology , 1990, Electrophoresis.

[35]  C. Fielding,et al.  Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.

[36]  W. A. Bradley,et al.  Triglyceride, high density lipoprotein, and coronary heart disease. , 1993, Consensus statement. National Institutes of Health Consensus Development Conference.

[37]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[38]  T. Arai,et al.  Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[39]  L. Havekes,et al.  Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  康二 梶波,et al.  Cholesteryl-Ester Transfer Activityの欠損を示す家族性高HDL血症の1家系 , 1987 .

[41]  A. Tall Plasma lipid transfer proteins. , 1986, Journal of lipid research.